These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38366286)

  • 21. A DELPHI study on aspects of study design to overcome knowledge gaps on the burden of disease caused by serogroup B invasive meningococcal disease.
    Marten O; Koerber F; Bloom D; Bullinger M; Buysse C; Christensen H; De Wals P; Dohna-Schwake C; Henneke P; Kirchner M; Knuf M; Lawrenz B; Monteiro AL; Sevilla JP; Van de Velde N; Welte R; Wright C; Greiner W
    Health Qual Life Outcomes; 2019 May; 17(1):87. PubMed ID: 31118091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.
    Bos JM; Rümke HC; Welte R; Spanjaard L; van Alphen L; Postma MJ
    Pharmacoeconomics; 2006; 24(2):141-53. PubMed ID: 16460135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of meningococcal serogroup B disease in children after implementation of routine infant 4CMenB vaccination in England: an active, prospective, national surveillance study.
    Mensah AA; Campbell H; Clark SA; Ribeiro S; Lucidarme J; Bai X; Borrow R; Ladhani SN
    Lancet Child Adolesc Health; 2023 Mar; 7(3):190-198. PubMed ID: 36736341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Invasive meningococcal disease in the Czech Republic - analysis of the epidemiological situation and vaccination strategy recommendations].
    Křížová P; Vacková Z; Musílek M; Kozáková J
    Epidemiol Mikrobiol Imunol; 2013 Dec; 62(4):138-47. PubMed ID: 24467175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genomic Characterization of Invasive Meningococcal Serogroup B Isolates and Estimation of 4CMenB Vaccine Coverage in Finland.
    Bodini M; Brozzi A; Giuliani M; Nohynek H; Vainio A; Kuusi M; De Paola R; Pizza M; Medini D; Toropainen M; Serino L; Muzzi A
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular characterization of invasive
    Sereikaitė E; Plepytė R; Petrutienė A; Stravinskienė D; Kučinskaitė-Kodzė I; Gėgžna V; Ivaškevičienė I; Žvirblienė A; Plečkaitytė M
    Front Cell Infect Microbiol; 2023; 13():1136211. PubMed ID: 36875527
    [No Abstract]   [Full Text] [Related]  

  • 27. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B
    Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218
    [No Abstract]   [Full Text] [Related]  

  • 28. Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease.
    La EM; Talbird SE; Kanadanian KV; Huang L; Fain J; Srivastava A
    Hum Vaccin Immunother; 2019; 15(4):978-986. PubMed ID: 30526279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
    Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
    BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp.
    Burman C; Alderfer J; Snow VT
    J Clin Pharm Ther; 2020 Apr; 45(2):270-281. PubMed ID: 31820483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of invasive Neisseria meningitidis from Atlantic Canada, 2009 to 2013: With special reference to the nonpolysaccharide vaccine targets (PorA, factor H binding protein, Neisseria heparin-binding antigen and Neisseria adhesin A).
    Tsang RS; Law DK; Gad RR; Mailman T; German G; Needle R
    Can J Infect Dis Med Microbiol; 2015; 26(6):299-304. PubMed ID: 26744586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of epidemiological and molecular data from invasive meningococcal disease surveillance in the Czech Republic, 1993-2020.
    Křížová P; Honskus M; Okonji Z; Musílek M; Kozáková J
    Epidemiol Mikrobiol Imunol; 2022; 71(3):148-160. PubMed ID: 36257794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic characterization and estimated 4CMenB vaccine strain coverage of 284
    Efron A; Brozzi A; Biolchi A; Bodini M; Giuliani M; Guidotti S; Lorenzo F; Moscoloni MA; Muzzi A; Nocita F; Pizza M; Rappuoli R; Tomei S; Vidal G; Vizzotti C; Campos J; Sorhouet Pereira C
    Hum Vaccin Immunother; 2024 Dec; 20(1):2378537. PubMed ID: 39037011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Invasive meningococcal disease epidemiology and characterization of Neisseria meningitidis serogroups, sequence types, and clones; implication for use of meningococcal vaccines.
    Stein-Zamir C; Shoob H; Abramson N; Block C; Keller N; Jaffe J; Valinsky L
    Hum Vaccin Immunother; 2019; 15(1):242-248. PubMed ID: 30156954
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding the Sequelae of Invasive Meningococcal Disease in the United States.
    Marshall GS; McCormick ZL; Johns JS; Verduzco-Gutierrez M; Herrera-Restrepo O; Harrison LH
    Infect Dis Ther; 2024 Nov; 13(11):2213-2220. PubMed ID: 39269567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Why the Anti-Meningococcal B Vaccination during Adolescence Should Be Implemented in Italy: An Overview of Available Evidence.
    Boccalini S; Zanella B; Landa P; Amicizia D; Bechini A; Innocenti M; Iovine M; Lecini E; Marchini F; Paolini D; Sartor G; Zangrillo F; Lai PL; Bonanni P; Panatto D
    Microorganisms; 2020 Oct; 8(11):. PubMed ID: 33138142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence.
    Pouwels KB; Hak E; van der Ende A; Christensen H; van den Dobbelsteen GP; Postma MJ
    Hum Vaccin Immunother; 2013 May; 9(5):1129-38. PubMed ID: 23406816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Invasive meningococcal disease in the Veneto region of Italy: a capture-recapture analysis for assessing the effectiveness of an integrated surveillance system.
    Baldovin T; Lazzari R; Cocchio S; Furlan P; Bertoncello C; Saia M; Russo F; Baldo V
    BMJ Open; 2017 May; 7(4):e012478. PubMed ID: 28465304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Invasive meningococcal disease in Chile seven years after ACWY conjugate vaccine introduction.
    Villena R; Valenzuela MT; Bastías M; Santolaya ME
    Vaccine; 2022 Jan; 40(4):666-672. PubMed ID: 34996641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Whole genome analysis of Neisseria meningitidis isolates from invasive meningococcal disease collected in the Czech Republic over 28 years (1993-2020).
    Honskus M; Krizova P; Okonji Z; Musilek M; Kozakova J
    PLoS One; 2023; 18(3):e0282971. PubMed ID: 36913385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.